Functional Biomarkers of Depression: Diagnosis, Treatment, and Pathophysiology

Overview

Journal Neuropsychopharmacology

Date 2011 Aug 5

PMID 21814182

Citations 176

Authors

Heath D Schmidt

Richard C Shelton

Ronald S Duman

Affiliations

Soon will be listed here.

Abstract

Major depressive disorder (MDD) is a heterogeneous illness for which there are currently no effective methods to objectively assess severity, endophenotypes, or response to treatment. Increasing evidence suggests that circulating levels of peripheral/serum growth factors and cytokines are altered in patients with MDD, and that antidepressant treatments reverse or normalize these effects. Furthermore, there is a large body of literature demonstrating that MDD is associated with changes in endocrine and metabolic factors. Here we provide a brief overview of the evidence that peripheral growth factors, pro-inflammatory cytokines, endocrine factors, and metabolic markers contribute to the pathophysiology of MDD and antidepressant response. Recent preclinical studies demonstrating that peripheral growth factors and cytokines influence brain function and behavior are also discussed along with their implications for diagnosing and treating patients with MDD. Together, these studies highlight the need to develop a biomarker panel for depression that aims to profile diverse peripheral factors that together provide a biological signature of MDD subtypes as well as treatment response.

Citing Articles

Neural signatures of emotional biases predict clinical outcomes in difficult-to-treat depression.

Fennema D, Barker G, ODaly O, Godlewska B, Carr E, Goldsmith K Res Dir Depress. 2025; 1:e21.

PMID: 40028885 PMC: 11869767. DOI: 10.1017/dep.2024.6.

Possible antidepressant mechanism of acupuncture: targeting neuroplasticity.

Xu N, He Y, Wei Y, Bai L, Wang L Front Neurosci. 2025; 19:1512073.

PMID: 40018358 PMC: 11865234. DOI: 10.3389/fnins.2025.1512073.

Long-term consumption of hydrogen-rich water provides hepatoprotection by improving mitochondrial biology and quality control in chronically stressed mice.

He Q, Lan X, Ding M, Zhang N PLoS One. 2025; 20(2):e0317080.

PMID: 39951412 PMC: 11828380. DOI: 10.1371/journal.pone.0317080.

Meta analysis of resting frontal alpha asymmetry as a biomarker of depression.

Luo Y, Tang M, Fan X Npj Ment Health Res. 2025; 4(1):2.

PMID: 39820155 PMC: 11739517. DOI: 10.1038/s44184-025-00117-x.

Precision Medicine in Depression: The Role of Proteomics and Metabolomics in Personalized Treatment Approaches.

Jaber M, Kahwaji H, Nasr S, Baz R, Kim Y, Fakhoury M Adv Exp Med Biol. 2024; 1456:359-378.

PMID: 39261438 DOI: 10.1007/978-981-97-4402-2_18.

References

von der Thusen J, Kuiper J, Van Berkel T, Biessen E . Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev. 2003; 55(1):133-66. DOI: 10.1124/pr.55.1.5. View

Dunbar J, Reddy P, Davis-Lameloise N, Philpot B, Laatikainen T, Kilkkinen A . Depression: an important comorbidity with metabolic syndrome in a general population. Diabetes Care. 2008; 31(12):2368-73. PMC: 2584197. DOI: 10.2337/dc08-0175. View

Capuron L, Dantzer R . Cytokines and depression: the need for a new paradigm. Brain Behav Immun. 2003; 17 Suppl 1:S119-24. DOI: 10.1016/s0889-1591(02)00078-8. View

Wang P, Simon G, Kessler R . The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res. 2003; 12(1):22-33. PMC: 6878402. DOI: 10.1002/mpr.139. View

Simen B, Duman C, Simen A, Duman R . TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry. 2006; 59(9):775-85. DOI: 10.1016/j.biopsych.2005.10.013. View

McIntyre R, Park K, Law C, Sultan F, Adams A, Lourenco M . The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. CNS Drugs. 2010; 24(9):741-53. DOI: 10.2165/11533280-000000000-00000. View

Gonul A, Akdeniz F, Taneli F, Donat O, Eker C, Vahip S . Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci. 2005; 255(6):381-6. DOI: 10.1007/s00406-005-0578-6. View

Lutter M, Sakata I, Osborne-Lawrence S, Rovinsky S, Anderson J, Jung S . The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. Nat Neurosci. 2008; 11(7):752-3. PMC: 2765052. DOI: 10.1038/nn.2139. View

Johnson J, Campisi J, Sharkey C, Kennedy S, Nickerson M, Greenwood B . Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines. Neuroscience. 2005; 135(4):1295-307. DOI: 10.1016/j.neuroscience.2005.06.090. View

10.

Dunn A, Swiergiel A, de Beaurepaire R . Cytokines as mediators of depression: what can we learn from animal studies?. Neurosci Biobehav Rev. 2005; 29(4-5):891-909. DOI: 10.1016/j.neubiorev.2005.03.023. View

11.

Papakostas G, Fava M . Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. Dialogues Clin Neurosci. 2009; 10(4):439-51. PMC: 3181892. View

12.

Nestler E, Barrot M, DiLeone R, Eisch A, Gold S, Monteggia L . Neurobiology of depression. Neuron. 2002; 34(1):13-25. DOI: 10.1016/s0896-6273(02)00653-0. View

13.

Schmidt H, Duman R . Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology. 2010; 35(12):2378-91. PMC: 2955759. DOI: 10.1038/npp.2010.114. View

14.

Koliatsos V, Clatterbuck R, Winslow J, Cayouette M, Price D . Evidence that brain-derived neurotrophic factor is a trophic factor for motor neurons in vivo. Neuron. 1993; 10(3):359-67. DOI: 10.1016/0896-6273(93)90326-m. View

15.

Sairanen M, Lucas G, Ernfors P, Castren M, Castren E . Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J Neurosci. 2005; 25(5):1089-94. PMC: 6725966. DOI: 10.1523/JNEUROSCI.3741-04.2005. View

16.

Hock C, Heese K, Muller-Spahn F, Huber P, Riesen W, Nitsch R . Increased cerebrospinal fluid levels of neurotrophin 3 (NT-3) in elderly patients with major depression. Mol Psychiatry. 2000; 5(5):510-3. DOI: 10.1038/sj.mp.4000743. View

17.

Aydemir O, Deveci A, Taneli F . The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29(2):261-5. DOI: 10.1016/j.pnpbp.2004.11.009. View

18.

Wong M, Kling M, Munson P, Listwak S, Licinio J, Prolo P . Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci U S A. 2000; 97(1):325-30. PMC: 26662. DOI: 10.1073/pnas.97.1.325. View

19.

Pariante C . Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids. Ann N Y Acad Sci. 2009; 1179:144-52. PMC: 2982725. DOI: 10.1111/j.1749-6632.2009.04978.x. View

20.

Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M . Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res. 2001; 105(1-2):45-55. DOI: 10.1016/s0165-1781(01)00315-8. View